ANL 29.19 Decreased By ▼ -0.61 (-2.05%)
ASC 20.15 Decreased By ▼ -0.25 (-1.23%)
ASL 24.10 Increased By ▲ 0.50 (2.12%)
BOP 8.25 Decreased By ▼ -0.01 (-0.12%)
BYCO 10.03 Increased By ▲ 0.15 (1.52%)
FCCL 21.91 Increased By ▲ 0.06 (0.27%)
FFBL 26.89 Decreased By ▼ -0.02 (-0.07%)
FFL 19.30 Decreased By ▼ -0.70 (-3.5%)
FNEL 8.33 Decreased By ▼ -0.41 (-4.69%)
GGGL 25.95 Decreased By ▼ -0.45 (-1.7%)
GGL 44.31 Decreased By ▼ -1.73 (-3.76%)
HUMNL 6.90 Decreased By ▼ -0.15 (-2.13%)
JSCL 21.30 Decreased By ▼ -0.32 (-1.48%)
KAPCO 38.90 Increased By ▲ 0.20 (0.52%)
KEL 3.81 Decreased By ▼ -0.09 (-2.31%)
MDTL 3.52 Decreased By ▼ -0.04 (-1.12%)
MLCF 43.68 Increased By ▲ 0.18 (0.41%)
NETSOL 156.95 Decreased By ▼ -1.55 (-0.98%)
PACE 7.22 Decreased By ▼ -0.23 (-3.09%)
PAEL 33.30 Decreased By ▼ -0.35 (-1.04%)
PIBTL 10.94 Decreased By ▼ -0.06 (-0.55%)
POWER 9.06 Decreased By ▼ -0.14 (-1.52%)
PRL 23.10 Increased By ▲ 0.10 (0.43%)
PTC 11.55 Decreased By ▼ -0.05 (-0.43%)
SILK 1.72 Decreased By ▼ -0.11 (-6.01%)
SNGP 50.10 Increased By ▲ 0.30 (0.6%)
TELE 14.90 Increased By ▲ 0.10 (0.68%)
TRG 159.26 Decreased By ▼ -0.19 (-0.12%)
UNITY 40.25 Decreased By ▼ -0.20 (-0.49%)
WTL 3.44 Decreased By ▼ -0.15 (-4.18%)
BR100 5,081 Decreased By ▼ -15.02 (-0.29%)
BR30 25,603 Decreased By ▼ -152.14 (-0.59%)
KSE100 47,281 Decreased By ▼ -37.53 (-0.08%)
KSE30 18,968 Decreased By ▼ -6.64 (-0.03%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
23,209
7624hr
Pakistan Cases
1,020,324
4,49724hr
7.53% positivity
Sindh
374,434
Punjab
354,904
Balochistan
30,019
Islamabad
86,602
KPK
142,799
World

Mexico's drug regulator says no plans for now to limit AstraZeneca vaccine

  • Mexico's drug regulator Cofepris said on Wednesday it has no current plans to limit the use of the Oxford/AstraZeneca COVID-19 vaccine to any age or group.
08 Apr 2021

MEXICO CITY: Mexico's drug regulator Cofepris said on Wednesday it has no current plans to limit the use of the Oxford/AstraZeneca COVID-19 vaccine to any age or group, after Britain's vaccine advisory committee cited safety concerns over its use on people under the age of 30.

Cofepris is investigating the issue and awaiting further information, it said in a statement to Reuters.